Cargando…
Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735070/ https://www.ncbi.nlm.nih.gov/pubmed/26657199 http://dx.doi.org/10.1038/bcj.2015.103 |
| _version_ | 1782413010851069952 |
|---|---|
| author | Ravandi, F Pigneux, A DeAngelo, D J Raffoux, E Delaunay, J Thomas, X Kadia, T Kantarjian, H Scheuenpflug, J Zhao, C Guo, W Smith, B D |
| author_facet | Ravandi, F Pigneux, A DeAngelo, D J Raffoux, E Delaunay, J Thomas, X Kadia, T Kantarjian, H Scheuenpflug, J Zhao, C Guo, W Smith, B D |
| author_sort | Ravandi, F |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4735070 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-47350702016-02-17 Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies Ravandi, F Pigneux, A DeAngelo, D J Raffoux, E Delaunay, J Thomas, X Kadia, T Kantarjian, H Scheuenpflug, J Zhao, C Guo, W Smith, B D Blood Cancer J Letter to the Editor Nature Publishing Group 2015-12 2015-12-11 /pmc/articles/PMC4735070/ /pubmed/26657199 http://dx.doi.org/10.1038/bcj.2015.103 Text en Copyright © 2015 Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
| spellingShingle | Letter to the Editor Ravandi, F Pigneux, A DeAngelo, D J Raffoux, E Delaunay, J Thomas, X Kadia, T Kantarjian, H Scheuenpflug, J Zhao, C Guo, W Smith, B D Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies |
| title | Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies |
| title_full | Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies |
| title_fullStr | Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies |
| title_full_unstemmed | Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies |
| title_short | Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies |
| title_sort | clinical, pharmacokinetic and pharmacodynamic data for the mek1/2 inhibitor pimasertib in patients with advanced hematologic malignancies |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735070/ https://www.ncbi.nlm.nih.gov/pubmed/26657199 http://dx.doi.org/10.1038/bcj.2015.103 |
| work_keys_str_mv | AT ravandif clinicalpharmacokineticandpharmacodynamicdataforthemek12inhibitorpimasertibinpatientswithadvancedhematologicmalignancies AT pigneuxa clinicalpharmacokineticandpharmacodynamicdataforthemek12inhibitorpimasertibinpatientswithadvancedhematologicmalignancies AT deangelodj clinicalpharmacokineticandpharmacodynamicdataforthemek12inhibitorpimasertibinpatientswithadvancedhematologicmalignancies AT raffouxe clinicalpharmacokineticandpharmacodynamicdataforthemek12inhibitorpimasertibinpatientswithadvancedhematologicmalignancies AT delaunayj clinicalpharmacokineticandpharmacodynamicdataforthemek12inhibitorpimasertibinpatientswithadvancedhematologicmalignancies AT thomasx clinicalpharmacokineticandpharmacodynamicdataforthemek12inhibitorpimasertibinpatientswithadvancedhematologicmalignancies AT kadiat clinicalpharmacokineticandpharmacodynamicdataforthemek12inhibitorpimasertibinpatientswithadvancedhematologicmalignancies AT kantarjianh clinicalpharmacokineticandpharmacodynamicdataforthemek12inhibitorpimasertibinpatientswithadvancedhematologicmalignancies AT scheuenpflugj clinicalpharmacokineticandpharmacodynamicdataforthemek12inhibitorpimasertibinpatientswithadvancedhematologicmalignancies AT zhaoc clinicalpharmacokineticandpharmacodynamicdataforthemek12inhibitorpimasertibinpatientswithadvancedhematologicmalignancies AT guow clinicalpharmacokineticandpharmacodynamicdataforthemek12inhibitorpimasertibinpatientswithadvancedhematologicmalignancies AT smithbd clinicalpharmacokineticandpharmacodynamicdataforthemek12inhibitorpimasertibinpatientswithadvancedhematologicmalignancies |